The company made this announcement on Tuesday, 6 December 2011 when the market was closed for a public holiday.
Meanwhile, the BSE Sensex was up 14.39 points, or 0.09% to 16,819.72.
On BSE, 14,000 shares were traded in the counter as against average daily volume of 1.09 lakh shares in the past one quarter.
The stock hit a high of Rs 444.10 and a low of Rs 441 so far during the day. The stock had hit a 52-week low of Rs 413.25 on 24 November 2011. The stock had hit a 52-week high of Rs 611.75 on 4 January 2011.
The stock had underperformed the market over the past one month till 5 December 2011, falling 13.34% compared with Sensex's 4.31% decline. The scrip had also underperformed the market over the past one quarter, declining 8.73% as against Sensex's 0.55% rise.
The large-cap drug maker has an equity capital of Rs 211 crore. Face value per share is Rs 5.
Ranbaxy Laboratories in a press release said its wholly owned subsidiary Ranbaxy Pharmaceuticals Inc has launched an authorized generic version of Caduet in the United States market, as part of an agreement with Pfizer Inc.
Ranbaxy Laboratories said Caduet is a fixed-dose combination of Atorvastatin-Amlodipine besylate which is presently marketed by Pfizer under the brand Caduet, which also contains a crystalline form of Atorvastatin. The product is indicated for patients suffering from both, high blood pressure and high levels of cholesterol, Ranbaxy said in a statement. Caduet generated total annual sales of $339 million in the US as per IMS-MAT September 2011 data, the company added. The company also said that it is making available the full range of the generic version of Caduet.
Commenting on the new launch, Mr Venkat Krishnan, Sr Vice President & Regional Director, Americas, Ranbaxy said, "The introduction of Atorvastatin-Amlodipine besylate tablets is a significant and important addition to our portfolio of cardio-vascular products, in the U.S. The launch further complements our resolve to bring high quality, affordable generic medicines as early as possible to the U.S healthcare system, benefiting a wider cross-section of people".
On a consolidated basis, Ranbaxy Laboratories reported a net loss of Rs 464.58 crore in Q3 September 2011 compared with a net profit of Rs 307.94 crore in Q3 September 2010. Net sales rose 7.7% to Rs 2022.76 crore in Q3 September 2011 over Q3 September 2010.
Ranbaxy Laboratories is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy serves its customers in over 125 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 46 countries and manufacturing operations in 7 countries. Ranbaxy is a member of the Daiichi Sankyo Group. Through strategic in-licensing opportunities and its hybrid business model with Daiichi Sankyo, a leading global pharma innovator headquartered in Tokyo, Japan, Ranbaxy is introducing many innovator products in markets around the world, where it has a strong presence. This is in line with the company's commitment to increase penetration and improve access to medicines, across the globe.
Powered by Capital Market - Live News
